BioMotiv
Accelerating Breakthrough Discoveries into Medicines

Portfolio

Portfolio

We are interested in licensing and developing technologies across all disease areas and in broad classes of therapeutics. We seek opportunities from the lead optimization stage through IND-enabling stages of development.

Allinaire Therapeutics

Source: Indiana University
Target: EMAP 2
Researchers: Irina Petrache, Matthias Clauss
Indication: Chronic Obstructive Pulmonary Disease


Aro Biotherapeutics

A biotechnology company focused on the research and development of Centyrins – a next-generation protein drug platform.

Source: Johnson & Johnson
Indication:  Oncology
Investors: Johnson & Johnson Innovation and BioMotiv

AdobeStock_134898335-1024x683.jpeg

Dodeca

Source: Confidential
Target: Confidential
Indication:  Acute Kidney Injury

 
Orca-Gray-Background.png

Dual Therapeutics

Source: Mt. Sinai School of Medicine, Case Western Reserve University
Target: PP2a Activators
Researchers: Goutham Narla, Michael Ohlmeyer, Matthew Galsky
Indication: Cancer

neurons-1773922-1024x683.jpg

Gladstone Institutes

Source: Gladstone Institutes
Target: Confidential
Researchers: Jorge Palop
Indication: Dravet's Syndrome

Inclera Therapeutics

A development company that helps scientists advance their technology towards commercialization.

 

Koutif Therapeutics

Source: University of Pittsburgh and United States Department of Veterans Affairs
Target: Fbxo3 inhibitor
Researchers: Rama Mallampalli, Beibei Chen
Indication:  Inflammatory diseases

Kodosil

Source: BioAtla
Target: IL-22 Inhibitors
Researchers: Bill Boyle
Indication: Inflammatory Bowel Diseases

OptiKira

Source: University of California, San Francisco; University of Washington
Target: IRE1a Inhibitors
Researchers: Feroz Papa, Scott Oakes, Bradley Backes, Dustin Maly
Indication: Retinitis Pigmentosa

 
Dual-Therapeutics-PP2A-Gray-Background-v2-e1469108286153.png

Orca Pharmaceuticals

Source: New York University
Target: RORy Inhibitors
Researchers: Dan Littman, Juh Hun
Indication: Psoriasis

Brickwell and AstraZeneca.png

SapVax

Source: University of Auckland
Target: Cancer Vaccine Platform (NY-ESO-1, Epstein-Barr Virus)
Researchers: Rod Dunbar, Margaret Brimble
Indication: Immuno-Oncology

Sujana Biotech

Source: Case Western Reserve University
Target: GBIba Inhibitor of Mac-1
Researchers: Daniel Simon, Edward Plow, Yunmei Wang
Indication: Anti-inflammatory